BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gembillo G, Siligato R, Cernaro V, Santoro D. Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist's Opinion. J Clin Med 2020;9:E1261. [PMID: 32357555 DOI: 10.3390/jcm9051261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Shikdar S, Borogovac A, Mohamad E, Khawandanah M. COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab. Thromb J 2021;19:75. [PMID: 34674707 DOI: 10.1186/s12959-021-00330-6] [Reference Citation Analysis]
2 Schrezenmeier H, Kulasekararaj A, Mitchell L, Sicre de Fontbrune F, Devos T, Okamoto S, Wells R, Rottinghaus ST, Liu P, Ortiz S, Lee JW, Socié G. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study. Ther Adv Hematol 2020;11:2040620720966137. [PMID: 33178408 DOI: 10.1177/2040620720966137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Sokol J, Nehaj F, Mokan M, Lisa L, Stasko J. COVID19 infection in a patient with paroxysmal nocturnal hemoglobinuria: A case report. Medicine (Baltimore) 2021;100:e25456. [PMID: 34011023 DOI: 10.1097/MD.0000000000025456] [Reference Citation Analysis]